ADENOSINE AND ANTIOXIDANT ENZYMES
腺苷和抗氧化酶
基本信息
- 批准号:2685481
- 负责人:
- 金额:$ 9.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-04-01 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:adenosine antioxidants catalase chemoprevention electron microscopy enzyme activity enzyme substrate free radical oxygen glutathione peroxidase hydrogen peroxide ischemia lactate dehydrogenases northern blottings organelles oxidative stress phosphorylation protein kinase C respiratory hypoxia site directed mutagenesis superoxide dismutase tissue /cell culture western blottings
项目摘要
Oxygen free radicals, such as singlet oxygen, superoxide anion and
hydroxyl radicals, are normal byproducts of oxygen utilization by the
tissue. Reducing the cellular load of these radicals is a major goal in
medicine since free radicals have been implicated in Alzheimer's disease,
Parkinson's disease, cancers, ischemia-reperfusion injuries, inflammation
and also in the aging process. An antioxidant defense system provides
protection of the cell from free radicals and comprises enzymes such as
superoxide dismutase (SOD), catalase CAT), glutathione peroxidase (GSH.Px)
and glutathione reductase (GR) and nonenzymatic antioxidants such as
vitamins A, C and E and reduced glutathione. The nucleoside adenosine, a
metabolite of ATP, provides protection to tissues during myocardial and
cerebral ischemia. While the mechanism of cytoprotection is not clear, we
have recently demonstrated that adenosine and an analog R-phenylisopropyl
adenosine (R-PIA) promote rapid activation (observed within 30 min) of
antioxidant enzymes by 2-3 fold by activating an AAR subtype coupled to
phospholipase C in a rat basophilic clone (RBL-2H3 cells). A23187 (a Ca2+
ionophore) and phorbol esters (activators of protein kinase C) both
mimicked activation of these enzymes via the A3AR. Inhibition of protein
kinase C by staurosporine attenuated activation of these enzymes elicited
by both R-PIA and phorbol esters. Furthermore, the activities of purified
preparations of antioxidant enzymes could be regulated by protein kinase
C-mediated phosphorylation. These data suggest that stimulation of the
A3AR leads to activation of antioxidant enzymes, and that this activation
process likely involves phosphorylation by protein kinase C.
The major aims of this study are:
l. To determine the mechanism(s) by which this rapid activation of the
A3AR on the cell surface leads to activation of antioxidant enzymes. This
study will focus mainly on protein kinase C and would specifically
determine whether antioxidant enzymes are substrates of protein kinase C
in vitro and whether the A3AR promotes in vivo phosphorylation of these
enzymes. In addition, site-directed mutagenesis of potential
phosphorylation sites will be performed to determine the potential site(s)
of phosphorylation by protein kinase C. These latter studies will involve
mutagenesis of epitope tagged cDNAs of the different antioxidant enzymes.
2. To determine whether activation of antioxidant enzymes via the A3AR
provides protection to cells during hypoxia or undergoing oxidative
stress. Oxidative stress to RBL-2H3 cells, bovine aortic endothelial cells
and cardiac myocytes will be induced by hypoxia the addition of hydrogen
peroxide to the culture medium or by the addition of a mixture of
xanthine/xanthine oxidase for periods ranging from 1-2 h. A3AR-mediated
protection will be assessed by determining the levels of reduced and
oxidized glutathione, malondialdehyde and by electron microscopic studies
of cellular organelles.
3. To determine the long term effect of A3AR activation on antioxidant
enzymes. Cells (RBL-2H3 and human endothelial cells) will be treated with
R-PIA for periods ranging from 12-48 h and the "steady state" activities
and levels of various antioxidant enzymes will be determined
spectrophometrically and by Western blotting, respectively. Northern
blotting studies will determine whether the A3AR can regulate the RNA
encoding these enzymes.
Taken together, these studies will explore a novel mechanism of
cytoprotection provided by adenosine and might contribute to the
development of new treatments for myocardial and cerebral ischemia.
氧自由基,如单线态氧、超氧阴离子和
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vickram Ramkumar其他文献
Vickram Ramkumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vickram Ramkumar', 18)}}的其他基金
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity
口服表没食子儿茶素没食子酸酯(EGCG)治疗顺铂耳毒性
- 批准号:
10163157 - 财政年份:2018
- 资助金额:
$ 9.87万 - 项目类别:
Oral Epigallocatechin Gallate (EGCG) for Treatment of Alzheimer's Disease Induced Hearing Loss
口服表没食子儿茶素没食子酸酯 (EGCG) 用于治疗阿尔茨海默病引起的听力损失
- 批准号:
10288729 - 财政年份:2018
- 资助金额:
$ 9.87万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
8579608 - 财政年份:2013
- 资助金额:
$ 9.87万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
8688964 - 财政年份:2013
- 资助金额:
$ 9.87万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
9288153 - 财政年份:2013
- 资助金额:
$ 9.87万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
9096039 - 财政年份:2013
- 资助金额:
$ 9.87万 - 项目类别:
Targeting Inflammation for the Amelioration of Cisplatin-Hearing Loss
针对炎症改善顺铂听力损失
- 批准号:
8180477 - 财政年份:2011
- 资助金额:
$ 9.87万 - 项目类别:
Role of adenosine A3 receptor in suppressing prostate cancer
腺苷A3受体在抑制前列腺癌中的作用
- 批准号:
7516278 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别:
Nerve Growth Factor and Transient Receptor Potential (TRPV1) Channel in Diabetic
糖尿病患者的神经生长因子和瞬时受体电位 (TRPV1) 通道
- 批准号:
7457520 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别:
相似海外基金
Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
- 批准号:
24K18002 - 财政年份:2024
- 资助金额:
$ 9.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Sustainable antioxidants for industrial process fluids
SBIR 第一阶段:工业过程流体的可持续抗氧化剂
- 批准号:
2222215 - 财政年份:2023
- 资助金额:
$ 9.87万 - 项目类别:
Standard Grant
Development of a new bone augmentation method that enables long-term survival and long-term functional expression of transplanted cells by antioxidants
开发一种新的骨增强方法,通过抗氧化剂使移植细胞能够长期存活和长期功能表达
- 批准号:
23K09272 - 财政年份:2023
- 资助金额:
$ 9.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Non-Invasive Probing Cellular Oxidative Stress and Antioxidants Therapeutic Effectiveness
非侵入性探测细胞氧化应激和抗氧化剂的治疗效果
- 批准号:
10652764 - 财政年份:2023
- 资助金额:
$ 9.87万 - 项目类别:
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
线粒体靶向新型阳离子腙抗氧化剂用于治疗先兆子痫
- 批准号:
10730652 - 财政年份:2023
- 资助金额:
$ 9.87万 - 项目类别:
Latent Antioxidants for Environmentally Responsible Polymer Formulations
用于环保聚合物配方的潜在抗氧化剂
- 批准号:
RGPIN-2018-04107 - 财政年份:2022
- 资助金额:
$ 9.87万 - 项目类别:
Discovery Grants Program - Individual
Contribution of antioxidants to regeneration of rotator cuff insertion
抗氧化剂对肩袖插入再生的贡献
- 批准号:
22K16720 - 财政年份:2022
- 资助金额:
$ 9.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of different doses of antioxidants(Vitamin E) intake on exercise induced oxidative stress, antioxidative capacity and chronic inflammation
不同剂量抗氧化剂(维生素E)摄入对运动引起的氧化应激、抗氧化能力和慢性炎症的影响
- 批准号:
22K11609 - 财政年份:2022
- 资助金额:
$ 9.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Polyunsaturated fatty acid (PUFA), inflammation and antioxidants
多不饱和脂肪酸 (PUFA)、炎症和抗氧化剂
- 批准号:
RGPIN-2019-05674 - 财政年份:2022
- 资助金额:
$ 9.87万 - 项目类别:
Discovery Grants Program - Individual
Suppressed methemoglobin formation of artificial red cell by liposomal antioxidants and its mechanism.
脂质体抗氧化剂抑制人工红细胞高铁血红蛋白形成及其机制
- 批准号:
22K12824 - 财政年份:2022
- 资助金额:
$ 9.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




